Resources Repository
-
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
North America | Mental Health | Chronic Disease/Risk | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
Resource PackPublication, Teaching Resource 2017Resource Pack: U.S. Opioid Epidemic
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public …
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public health crisis, requiring an urgent coordinated response and innovative scientific solutions. This resource pack was curated for educators and students interested in how decision analytic methods and tools can be applied to the problem of opioid addiction.
North America | Mental Health | Chronic Disease/Risk | Preferences/Values | Evidence Synthesis | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2016Measuring Benefits of Opioid Misuse Treatment: HRQOL of Opioid-Dependent Individuals and Spouses
This study sought to understand how the general public views the quality of life effects …
This study sought to understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. The study design was a cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014, with a total of 2054 randomly selected adults, of whom 51.1% were male. The mean individual utility ranged from 0.574 for active injection…
North America | Mental Health | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Economics/Finance | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
North America | Mental Health | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
North America | Chronic Disease/Risk | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2024Disparities in TB Incidence by Race & Ethnicity Among the U.S.-Born Population in the U.S., 2011 to 2021
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born …
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born individuals from 2011 to 2021. Using national TB registry data, time-series analysis was conducted, stratifying by race/ethnicity and adjusting for age, year, and state of residence. Results indicate persistent disparities, with incidence rate ratios as high as 14.2 for American Indian or Alaska Native (AI/AN) females compared to non-Hispanic White individuals. Relative disparities were more pronounced for females, younger individuals,…
North America | Chronic Disease/Risk | Infectious Diseases | Health/Medicine -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
North America | Chronic Disease/Risk | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Clinical Care | Health/Medicine -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
North America | Chronic Disease/Risk | Mathematical Models | Cost-Effectiveness Analysis | Clinical Care -
ArticlePublication 2020Data-Driven Management of Post-Transplant Medications
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs as a mechanism to reduce their …
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs as a mechanism to reduce their risk of organ rejection. However, because of the diabetogenic effect of these drugs, this practice exposes them to a greater risk of new-onset diabetes after transplantation (NODAT), and hence, becoming insulin dependent. This study develops effective medication management strategies to address the common conundrum of balancing the risk of organ rejection versus that of NODAT. The article presents a robust…
North America | Chronic Disease/Risk | Mathematical Models | Operations Research | Health/Medicine